Abstract #308859

Background

High B7-H3 Expression Levels in Solid Tumors

- **Potential indications**: High B7-H3 expression is present in solid tumors such as lung, colorectal, sarcoma, melanoma, and breast cancer.

- **Key ELigibility Criteria**: Patients must have high B7-H3 expression levels and be suitable candidates for treatment with MGC018.

Study Design and Objectives

- **High B7-H3 Expression Levels**: Patients with high B7-H3 expression levels may benefit from treatment with MGC018.

- **Rationale**: MGC018 is a novel ADC with a doxorubicin payload, targeting B7-H3-expressing tumors.

Results

- **Enrollment Status**: 25 patients enrolled as of May 11, 2020.

Safety Summary

- **Related Adverse Events**: Common adverse events include lymphocyte count decreased, fatigue, and pyrexia.

- **Percent Change of Target Lesions**: Best percent change of target lesions by MGC018 dose level and tumor type.

Conclusions

- **MGC018** has a promising safety profile, with manageable hematologic and skin toxicity.

- **Future Studies**: Further exploration of MGC018 in other tumor types and in combination with other therapies.

Preliminary Dose Escalation Results from a Phase 1/2, First-in-Human Study of MGC018 (Anti-B7-H3 Antibody-Drug Conjugate) in Patients with Advanced Solid Tumors

John Powerdery, Sekwon Jang, Juniper Scriber, Deryk Loo, Chet Bohac, Alexander Spira, Manish Sharma

*BioOncology, Huntersville, NC; *Inova Schar Cancer Institute Fairfax, VA; *Macrogenics, Inc., Rockville, MD; *Virginia Cancer Specialists, Fairfax, VA; *START Midwest, Grand Rapids, MI

bohac@macrogenics.com

Presented at the ASCO20 Virtual Scientific Program, May 29–31, 2020

MGC018 Antibody-Drug Conjugate with Duocarmycin-basier Linked Payload

- MGC018 is a novel ADC targeting B7-H3-expressing tumors.

Rationale

- B7-H3 is highly expressed in multiple solid tumors, with limited expression in normal tissue.

- MGC018 is a novel ADC that delivers a doxorubicin payload to dividing and non-dividing B7-H3-expressing cells.

Grade ≥ 3 Related Adverse Events

- **Event that Resulted in Drug MGC018 Dose Reduction**: Treatment with MGC018 resulted in dose reduction for several patients.

- **Adverse Event ≥ Grade 3**: A list of adverse events that are ≥ Grade 3 in severity.

- **Percent Change of Target Lesions**: Best percent change of target lesions by MGC018 dose level and tumor type.

- **Percent Change of Target Lesions**: Response to MGC018 treatment, including significant reduction in tumor burden.

- **Tumor Response**: Response rates and progression-free survival for patients treated with MGC018.

- **Conclusions**: MGC018 has an acceptable safety profile, with manageable hematologic and skin toxicity, and evidence of antitumor activity.

- **Future Studies**: Further exploration of MGC018 in other tumor types and in combination with other therapies.